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Abstract

Introduction: Repetitive, brief coronary artery occlusions produce collateral development in experimental
animals. This model causes coronary collateralization in a highly reproducible fashion, but the process is very
labor intensive. We report the design and use of a fully automated hydraulic coronary occlusion device capable
of producing repetitive coronary occlusions and enhancement of coronary collateral development in
dogs. Methods: The device consists of analog electronics that allow adjustment of occlusion number, frequency,
pressure and duration, and mechanical components responsible for the coronary occlusion. The motor and
piston of the device are coupled to a chronically implanted hydraulic vascular occluder placed around the left
anterior descending coronary artery (LAD) of dogs instrumented for measurement of systemic and coronary
hemodynamics. One group of dogs (n=6) underwent brief (2 min) LAD occlusions once per hour, eight times per
day, 5 days/week for 3 weeks to stimulate collateral development (measured using radioactive microspheres).
Another group of dogs (n=6) that did not receive repetitive occlusions served as controls. Results: The device
reproducibly produced repetitive LAD occlusions for the duration, frequency, and time interval initially
programmed. A time-dependent increase in transmural collateral blood flow was observed in dogs undergoing
repetitive occlusions using the device. Collateral blood flow was unchanged in dogs that did not undergo
occlusions. Discussion: The automated occluder device reliably produces repetitive coronary occlusions and may
facilitate further study of coronary collateral development in response to chronic myocardial ischemia.

Keywords
Angiogenesis, Automated coronary occluder device, Coronary collateral circulation, Dog, Methods, Myocardial
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1. Introduction
Development of coronary collateral blood vessels occurs in response to chronic myocardial ischemia. Coronary
collaterals are important alternative sources of blood flow to ischemic myocardium that improve contractile
function and reduce injury to subsequent ischemic events. The growth of new collateral vessels (termed
“angiogenesis”) and the enlargement of preexisting collaterals occur as a result of the concerted actions of
several angiogenic mitogens that are released during ischemia Banai et al., 1994, Lazarous et al.,
1996, Matsunaga et al., 2000, Matsunaga et al., 2002, Schaper, 1993, Sharma & Schaper, 1993, Tessmer et al.,

2002, Weihrauch et al., 1998. Repetitive episodes of brief coronary artery occlusion and reperfusion have been
shown to produce coronary collateral development in a variety of animal species Kersten et al., 1997, Kersten et
al., 1999, Kersten et al., 1995 and may also have a pathophysiological basis in humans with coronary artery
disease (Fujita et al., 1988). This repetitive coronary occlusion model produces collateralization in a highly
reproducible fashion, but the process is very labor intensive because brief (typically between 1 and 3 min
duration) coronary occlusions interspersed with reperfusions must be performed at regular intervals (15–120
min) several times per day (4–24) for several weeks (3–12) depending on the animal species used and the
degree of collateral development desired (Kersten et al., 1999).
We report the design, construction, and use of an automated hydraulic coronary artery occlusion device capable
of temporally producing the repetitive brief coronary occlusions of different durations and occurring at different
intervals required to reliably develop coronary collaterals in dogs. The two-part system consists of an electric
control interface coupled to mechanical components that drive and retract a piston responsible for hydraulic
occlusion and reperfusion of a canine coronary artery in vivo. The device was rigorously constructed of very
durable components to withstand the typical activities of conscious, chronically instrumented dogs over a span
of several weeks of continuous use. We used this automated coronary occlusion device to verify our previous
results Kersten et al., 1995, Kersten et al., 1997, indicating that repetitive, brief (2 min) coronary occlusions
conducted eight times per day, 5 days/week for 3 weeks stimulate the development of the coronary collateral
circulation. We have previously demonstrated that this model of repetitive coronary occlusion produces
collateral development in dogs as indicated by time-dependent increases in collateral blood flow, reductions in
reactive hyperemic responses, and improvements in regional contractile function during acute coronary artery
occlusion Kersten et al., 1995, Kersten et al., 1997.

2. Methods
2.1. Use and care of animals

All experimental procedures and protocols used in this investigation were reviewed and approved by the Animal
Care and Use Committee of the Medical College of Wisconsin. Furthermore, all conformed to the “Guiding
Principles in the Care and Use of Animals” of the American Physiological Society and were in accordance with
the “Guide for the Care and Use of Laboratory Animals” of the National Institutes of Health (National Academy
Press, Washington, DC, 1996).

2.2. General device design and specifications

The device consists of two major elements constructed of commercially available parts: the user interface and
its associated analog electronics and the mechanical components responsible for coronary artery occlusion (Fig.
1). These two main components are housed in separate heavy-gauge aluminum boxes that are joined by a
circular conducting connection cable. A schematic diagram detailing the electronic design of the device is
illustrated in Fig. 2. For simplicity, a functional schematic has also been depicted (Fig. 3). The user interface
contains two circuit boards manufactured in our laboratory. The top circuit board contains the front panel
components (i.e., user controls) including an error fault LED and a digital occlusion counter display covered with
a protective membrane. The bottom circuit board contains the main logic circuitry that consists of discrete
devices and CMOS integrated circuits powered by four AA batteries arranged in parallel to yield ∼6 V. The
average quiescent power drain is 6 mA, with current bursts approaching 100 mA during motor movement. The
device is capable of imparting varying hydraulic pressures that are more than sufficient to occlude canine
coronary arteries in vivo.

Fig. 1. Schematic illustrations (top panels) and corresponding photographs (bottom panels) depicting the
electrical (A) and the mechanical (B) components of the automatic coronary occlusion device. (1–3) Motor end
cap, body, and shaft. (4 and 5) Shaft bearing and coupler. (6) Park-sense switch. (7 and 8) Piston with rubber
syringe tip. (9) Motor lock screws. (10) Luer-lock fitting with rubber gasket. (11) Side mount screws.

Fig. 2. Detailed schematic illustrating the electronic design of the automated hydraulic coronary
occlusion device.

Fig. 3. Functional schematic illustrating operational control and features of the automated hydraulic coronary
occlusion device.

2.3. User control interface

The front panel of the user control interface contains a power switch (TT11AGPC1; Augat, Mansfield, MA),
subcub six-digit component counter display (SubCub 1000; Red Lion Controls, York, PA), and forward, retract,
and zero buttons (39-424; Grayhill, LaGrange, IL). An adjustable potentiometer controls the occlusion pressure
(381N-10K; Clarostat, Richardson, TX). Switches allow for variation in the duration (56DP30-01-2-AJN; Grayhill),
number (56DP30-01-1-AJN; Grayhill), and time interval (TT21PAGPC1; Augat) between occlusions. The occlusion
durations ranging between 15 and 180 s may be preset using the control panel. The number of occlusions
performed each day may be fixed between 1 and 10 or may be set to a “continuous” mode that allows for a
virtually unlimited number of daily occlusions that cease only as a result of power failure or mechanical
malfunction. The time duration between each occlusion may also be preset to 15, 30, or 60 min (Fig. 1).

2.4. Mechanical occluder components

A Delrin cylinder is attached to an aluminum box using heat-annealed Plexiglas end caps (Fig. 1B). Delrin and
heat-annealed Plexiglas were specifically chosen for long-term durability and superior machining characteristics.
The cylinder aligns the park-sense circuit and houses the motor shaft and body (1516E002SLT 115/2 900:1 K185;
Micro Mo, Clearwater, FL), the shaft bearing and coupler, and the main piston. The piston is designed to accept
the rubber tip from a standard 20-ml syringe (Becton-Dickinson, Franklin Lakes, NJ) and contains 4 ml of distilled
water. A luer-locked fitting with a rubber gasket to prevent leakage is attached to the Delrin cylinder and
accepts nondistensible tubing that is attached to a relief valve (3-206-900; General Valve, Fairfield, NJ) and the
chronically implanted coronary artery occluder (see below).

2.5. Device operation

The temporal function of the device is determined by the status of the decade counter, assuming the total
supply voltage is sufficient to power the device. After powering “on,” the device is inoperable for a 10-s circuit
initialization period. The device then enters a “default standby” mode as indicated by the “wait” state in Fig. 3.
An occlusion cycle is generated after the occlusion interval is timed out or by manual depression of the forward
button on the control interface after device initiation. In the “forward” mode (logic “0”), a complementary pair
of transistors (shown as blocks in Fig. 3) is biased to produce forward movement of the motor. This motor
movement creates torque against the combined load of the piston, cylinder, and coronary occluder and
simultaneously imparts a voltage on the comparator input (filter out). Motor movement is discontinued when
this voltage exceeds the preset voltage of the pressure potentiometer on the user interface. The minimum
pressure setting required to adequately occlude the coronary artery is determined by the user as the pressure
associated with complete cessation phasic coronary blood flow velocity. The device must achieve the desired
pressure within 10 s or it will enter a “shutdown” operational mode. Once the desired pressure has been
reached, the comparator out drives a one shot that sequences the decade counter to an occlude mode, resets
the previous value of the filter out, and disables the 10-s shutdown counter. When the occlusion has been
completed, the timer enters a logic “1” that provides the drive for a complementary pair of transistors
associated with the “reverse” mode of motor operation and also reactivates the 10-s shutdown timer. The
piston then returns to the original position from which only forward motor movements are subsequently
possible. The decade counter is then reset, and the device enters a “wait” state of operation. The occlusion
count display also indicates that a successful occlusion was completed.

2.6. Automatic shutdown

The device was designed with an automatic shutdown feature to prevent permanent coronary occlusion due to
malfunction. Several possible events during routine operation may cause the device to automatically shutdown,
resulting in the illumination of the fault LED on the control panel. For example, a low battery condition occurs
when the supply voltage falls below 4.8 V and results in automatic shutdown. Device shutdown will also occur if

the duration of forward or reverse piston movements exceeds 10 s. The forward and reverse piston movements
and the decade counter function are disabled when a fault condition is detected. Importantly, an inline valve
relieves hydraulic pressure in the closed coronary occluder pathway during any fault condition. This safety
feature prevents inadvertent prolonged occlusion of the coronary artery from occurring.

2.7. Surgical instrumentation

The implantation of instruments has been previously described in detail Kersten et al., 1995, Kersten et al., 1997.
Briefly, conditioned mongrel dogs (n=12) of either sex weighing between 25 and 30 kg were fasted overnight
and anesthetized with intravenous propofol (8 mg/kg). After endotracheal intubation, anesthesia was
maintained with isoflurane (inspired concentration between 1.5% and 2.0%) in 100% O2 using positive pressure
ventilation. Fluid deficits were replaced with 500-ml 0.9% saline, which was continued at a rate of 3 ml/kg/h for
the duration of the surgery. Acid–base status and arterial blood gas tensions were maintained within the normal
range by adjustment of respiratory rate and tidal volume. Temperature was maintained with a heating blanket.
Under sterile operating conditions, a thoracotomy was performed in the left fifth intercostal space. The phrenic
nerve was identified and protected. The pericardium was opened and the heart was temporarily suspended in a
pericardial cradle. Heparin-filled catheters were positioned in the right atrial appendage and thoracic aorta for
administration of fluid and measurement of arterial blood pressure, respectively. A heparin-filled catheter was
also placed in the left atrial appendage for the administration of radioactive microspheres. A miniature hydraulic
occluder (In Vivo Metric, Healdsberg, CA) was positioned around the left anterior descending coronary artery
(LAD) for the production of coronary artery occlusion and reperfusion. A precalibrated Doppler flow probe was
positioned around the LAD immediately distal to the hydraulic occluder for measurement of phasic coronary
artery blood flow velocity. All instrumentation was secured, tunneled between the scapulae, and exteriorized via
several small incisions. The pericardium was left open, the chest wall was closed in layers, and the
pneumothorax was evacuated by a chest tube. Each dog was fitted with a jacket (Alice King Chatham, Los
Angeles, CA) to prevent damage to the instruments, the catheters, and the hydraulic occlusion device that were
contained in aluminum boxes within the jacket pockets (Fig. 4). All dogs received epidural morphine (0.1 mg/kg)
for postoperative analgesia. Antibiotic prophylaxis consisted of cephalothin (1 g) and gentamicin (4.5 mg/kg).
Anesthesia was discontinued and emergence was allowed to occur. Dogs were allowed to recover for 7 days
before subsequent experimentation.

Fig. 4. Photograph depicting the aluminum boxes containing the electrical and mechanical components of the
automated hydraulic coronary occlusion device stored in the jacket pockets of a typical conscious, chronically
instrumented dog.

2.8. Experimental protocol

Systemic and coronary hemodynamics were monitored daily, recorded on a polygraph (Model 7758A; HewlettPackard, San Francisco, CA), and digitized by a computer interfaced with an analog-to-digital converter. One
group of dogs (n=6) was assigned to receive 2-min LAD occlusions at hourly intervals eight times per day, 5
days/week for 3 weeks using the automated occlusion device. We have previously demonstrated that this
schedule of repetitive brief coronary occlusions produces an extensive coronary collateral circulation in this
canine model Kersten et al., 1995, Kersten et al., 1997. Hemodynamics was monitored before, during, and after
each occlusion. A second group of dogs (n=6) was instrumented identically but did not undergo repetitive
coronary occlusions (sham). Transmural coronary collateral blood flow was assessed using the radioactive
microsphere technique at 1, 7, 14, and 21 days of repetitive LAD occlusions. At the completion of the
experiment, each dog was euthanized with an overdose of sodium pentobarbital, and the position of implanted
instruments was confirmed.

2.9. Measurement of regional myocardial perfusion

Microspheres (15±2 μm, mean±S.D.) labeled with 95Nb, 141Ce, and 103Ru were used to measure myocardial
perfusion as previously described Domenech et al., 1969, Kersten et al., 1995, Warltier et al., 1981. Briefly,
microspheres were administered into the left atrium as a bolus. A few seconds before injection, a timed
collection of reference arterial blood flow was started from the aortic catheter at a rate of 7 ml/min for 3 min.
Transmural tissue samples were selected from the ischemic region and subdivided into subepicardial,
midmyocardial, and subendocardial layers of approximately equal thickness. Samples were weighed and the
activity of each isotope was determined. Similarly, the activity of each isotope in the reference blood flow
sample was assessed. Tissue blood flow (ml/min/g) was calculated as QrCm/Cr, where Qr is the rate of withdrawal
of the reference blood flow sample (ml/min), Cm is the activity (cpm/g) of the myocardial tissue sample, and Cr is
the activity of the reference blood flow sample. Transmural blood flow was considered to be the average of the
subepicardial, midmyocardial, and subendocardial blood flows.

2.10. Statistical analysis

Statistical analysis of data between groups was performed using analysis of variance (ANOVA) with repeated
measures followed by Student–Newman–Keuls' test. A probability (P) value less than .05 was considered
statistically significant. All data are expressed as means±S.E.M.

3. Results
All dogs survived the surgical instrumentation without complication. The postoperative course of each dog was
also uncomplicated. No failures or malfunction of the automated occlusion device were observed during the
course of experimentation. Each occlusion produced by the device completely abolished LAD blood flow velocity
for the duration, frequency, and time interval initially programmed (Fig. 5). No difficulties were observed in the
adjustment of minimal pressure required to obtain LAD occlusion. Only slight adjustments in this minimal
occlusion pressure were required over the 3-week duration of each experiment. A time-dependent increase in
transmural coronary collateral blood flow was observed in dogs undergoing repetitive LAD occlusions using the
automated coronary occlusion device (Fig. 6). In contrast, transmural collateral blood flow was unchanged in
dogs that were not exposed to repetitive occlusions.

Fig. 5. Changes in phasic LAD coronary artery blood flow velocity in response to activation of the automated
occlusion system. Representative chart recording illustrating blood flow velocity under resting conditions (A), at
the initiation (B), and at the completion (C) of a coronary artery occlusion and at the peak reactive hyperemic
response during reperfusion (D).

Fig. 6. Temporal increases in transmural coronary collateral blood flow in the ischemic (LAD) region in dogs
undergoing repetitive brief coronary occlusions using the automated device on experimental days 1, 7, 14, and
21. *P<.05, significantly different from sham.

4. Discussion
In the current investigation, we report the design, operation, and application of an automated hydraulic
occlusion device to reproducibly cause coronary collateralization in conscious dogs. The results indicate that the
repetitive brief occlusions produced by the device progressively increase transmural coronary collateral blood
flow over a 3-week period to a similar degree as has been observed in our previous studies Kersten et al.,
1995, Kersten et al., 1997, Matsunaga et al., 2000, Matsunaga et al., 2002, Weihrauch et al., 1998 using the
more laborious manual occlusion method. The current report describes the use of this device in dogs, but the
device may also be used in other experimental animal species with an appropriately sized implanted coronary
occluder and making adjustments in minimal occlusion pressure on the control interface. The device was
technically difficult to design and build, but all of the parts used in its construction are readily available from
commercial sources, and a capable engineer should be able to replicate the device using the design information
provided in this report. Additional details regarding device fabrication are available from the authors upon
request.
Development of the automated coronary occlusion device allows laboratory personnel to enroll multiple dogs in
a single protocol limited only by the number of occlusion systems. Researchers are also able to work on
additional protocols simultaneously with occasional monitoring of each dog. A previous experiment from our
laboratory used the current device to deliver 2-min coronary artery occlusions once each hour, 24 h/day for 7
days. The benefits to automating this process are obvious, as manual occlusion would require multiple shifts of
laboratory personnel and also would prevent the dog from sleeping for the duration of the protocol.

Previous studies have reported the design and implementation of devices designed to produce repetitive
vascular occlusion. Rubin, Quilter, and Battagin (1978) initially described an integrated circuit-based automatic
timer device for the repetitive inflation of limb pneumatic cuffs. More recently, Caldwell et al. (1989) reported
the design of an automatic coronary occluder system that shares several similarities with the current device. In
particular, the electronics of the present and previous (Caldwell et al., 1989) devices make use of similar timer,
decade counter, one shot driver, and comparator designs. However, these elements represent standard
approaches in electrical engineering design. Importantly, the previously described device (Caldwell et al.,
1989) was not subsequently validated in an established model of coronary collateral development that requires
over 100 successful brief coronary occlusions and reperfusions over a span of 3 weeks. In comparison, the
reliability of the current device is exceptional as demonstrated by successful performance in ∼50 dogs
instrumented with the automated occlusion system over a 1-year period. In addition, the current device
incorporates many features that increase the longevity, improve the mechanical performance, and enhance the
safety of the automated occlusion device. The mechanical and electrical components were strictly separated in
individual aluminum boxes to ensure that the electronic circuit boards remained clean and dry during prolonged
use. The previously described device (Caldwell et al., 1989) combined the mechanical and electrical units in a
single box, and a hydraulic leak in the syringe system may have theoretically damaged the electronic
components under these circumstances.
A fail-safe mechanism for battery loss was incorporated into the present design. A low battery state will render
the device inactive at any time during its normal operation and allow complete decompression of the hydraulic
pressure in the coronary occluder via an inline valve during this fault condition. Automatic motor reversal and
subsequent device shutdown will also occur if forward motor movement time exceeds 10 s. These objectives are
important because the previous device may have maintained complete mechanical coronary occlusion if a
power failure occurred before subsequent motor reversal. Such a situation may lead to the development of an
acute myocardial infarction or lethal cardiac arrhythmia. The present occluder design used a damped park
switch rather than a rear plunger stop as described in the previously characterized occlusion system (Caldwell et
al., 1989). This park switch was concentrically located behind the piston and contained a coil spring load that
acted as a shock absorber for the piston. This important design modification alleviates unnecessary wear on the
motor and lead screw. The present device employed an unique approach to reset the motor load filter output.
When reset, the pressure potentiometer circuit will detect a voltage value without any residual voltage (such as
may have been generated by the previous motor cycle) to ensure that the desired occlusion pressure is always
achieved. The forward and reverse switches on the user control panel were also debounced to eliminate
inadvertent occlusion or reperfusion by the user or those accidentally generated by the dog's movements.
There are a number of potential limitations in the current automated coronary occlusion device design and
operation that require additional comment. We have found that the batteries should be routinely replaced
every 72 h to ensure an adequate system power. Although device integrity is rarely compromised, several device
components require occasional maintenance. The rubber syringe tip mounted on the motor piston head needs
to be checked occasionally and may show substantial wear or require replacement after several hundred
occlusion-reperfusion cycles. The cable connecting the user control interface to the occlusion device should be
checked periodically and replaced as needed because pin corrosion occurs intermittently despite gold plating.
Mechanical malfunction of the device after battery replacement is most often associated with excessive motor
wear and is consistently resolved by replacing the motor. The hydraulic pressures within the coronary occluder
that were generated by the device were not specifically measured in situ in the current investigation. A previous
study (Caldwell et al., 1989) demonstrated that hydraulic pressures as great as 1000 mm Hg may be developed
in this type of automated device. Instead, we choose to manually adjust the pressure potentiometer in order to
obtain a minimum pressure required to occlude the coronary artery. This technique mimics the process of
hydraulic occlusion with manual inflation, may act to reduce the risk of coronary vascular damage from

excessive device-induced occlusion pressure, and may limit the possibility of inadvertently rupturing the cuff of
the chronically implanted occluder. Repetitive coronary artery occlusions may have an impact on the arterial
structure of the LAD coronary artery at the site of the hydraulic occluder. However, classification of histological
abnormalities in this localized region has not yet been performed.
In summary, we report the details of a new automated hydraulic coronary occlusion device and describe the use
of this device for the induction of coronary collateral growth in conscious, chronically instrumented dogs. The
results indicate that the device is safe, allows great flexibility in occlusion programming, and delivers consistent,
reliable performance over several weeks of continual use in this setting. The device will facilitate further study of
coronary collateral development in response to chronic myocardial ischemia.
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